मूलभूत आँकड़े
| CIK | 1304161 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pharma-Bio Serv, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SE |
|
| June 16, 2025 |
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2025 EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2025 DORADO, PUERTO RICO / ACCESS Newswire / June 16, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 16, 2025 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2025 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 21, 2025 | ||
| March 17, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2025 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File |
|
| March 17, 2025 |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2025 EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2025 DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and al |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO |
|
| February 28, 2025 |
Amended and Restated Code of business conduct and ethics for senior management EXHIBIT 14.1 PHARMA-BIO SERV, INC. Amended and Restated Code of Business Conduct and Ethics Ethics Pharma-Bio Serv, Inc. and each of its employees, officers and directors, who we collectively refer to as our “associates,” must conduct their affairs with uncompromising honesty and integrity. Business ethics are no different than personal ethics. The same high standard applies to both. Associates ar |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 Ph |
|
| January 29, 2025 |
EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Scienza Labs, Inc. Puerto Rico Pharma-Bio Serv S.L. Spain Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil |
|
| January 29, 2025 |
Pharma-Bio Serv Announces Full Year Results EXHIBIT 99.1 Pharma-Bio Serv Announces Full Year Results DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied pro |
|
| January 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 29, 2025 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 29, 2025 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 29, 2025 |
Pharma-Bio Serv Announces Special Dividend EXHIBIT 99.1 Pharma-Bio Serv Announces Special Dividend January 29, 2025 DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2025 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, foo |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, INC. |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SER |
|
| September 16, 2024 |
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2024 EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2024 DORADO, PUERTO RICO / ACCESSWIRE / September 16, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and a |
|
| September 16, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 16, 2024 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission F |
|
| June 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2024 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 14, 2024 |
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2024 EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2024 DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allie |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 Pharma-Bio Se |
|
| May 2, 2024 |
Amendment to Pharma-Bio Serv, Inc. 2014 Long-Term Incentive Plan. EXHIBIT 10.1 AMENDMENT TO THE PHARMA-BIO SERV, INC. 2014 LONG-TERM INCENTIVE PLAN WHEREAS, Pharma-Bio Serv, Inc., a Delaware corporation (the “Company”), currently maintains and sponsors the Pharma-Bio Serv, Inc. Long-Term Incentive Plan (the “Plan”); and WHEREAS, Section 12(a) of the Plan provides that the Board of the Directors of the Company (“Board”) may amend the Plan from time to time; and W |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2024 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 8, 2024 | ||
| April 8, 2024 | ||
| March 18, 2024 |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2024 EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2024 DORADO, PUERTO RICO / ACCESSWIRE / March 18, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and al |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 Pharma-Bio |
|
| March 18, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 18, 2024 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 Ph |
|
| January 30, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 29, 2024 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 30, 2024 |
EXHIBIT 99.1 January 29, 2024 Pharma-Bio Serv Announces Full Year Results DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2024 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, fo |
|
| January 29, 2024 |
EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Scienza Labs, Inc. Puerto Rico Pharma-Bio Serv S.L. Spain Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, INC. |
|
| December 21, 2023 |
Pharma-Bio Serv Announces Special Dividend EXHIBIT 99.1 Pharma-Bio Serv Announces Special Dividend December 21, 2023 DORADO, PUERTO RICO / ACCESSWIRE / December 21, 2023 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied prod |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 21, 2023 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 14, 2023 |
Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2023 EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2023 September 14, 2023 DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2023 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, med |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SER |
|
| September 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 14, 2023 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission F |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2023 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 14, 2023 |
Pharma-Bio Serv Announces Results for the Three and Six Months Ended April 30, 2023 EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Three and Six Months Ended April 30, 2023 June 14, 2023 DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2023 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical devic |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SE |
|
| May 31, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 31, 2023 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 1, 2023 | ||
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 1, 2023 |
Because our business is concentrated in the life science and medical devices industries in Puerto Rico, the United States, Europe and Brazil, any changes in those industries or in those markets could impair our ability to generate revenue and realize a profit. |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2023 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File |
|
| March 17, 2023 |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2023 EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2023 March 17, 2023 DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2023 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmet |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2023 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 1, 2023 |
Pharma-Bio Serv Announces Special Dividend EXHIBIT 99.1 Pharma-Bio Serv Announces Special Dividend March 1, 2023 DORADO, PUERTO RICO / ACCESSWIRE / March 1, 2023 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, t |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 Ph |
|
| February 9, 2023 |
Amended and Restated Bylaws of Pharma-Bio Serv Inc. EXHIBIT 3.1 AMENDED AND RESTATED BYLAWS OF PHARMA-BIO SERV INC. (a Delaware corporation) ARTICLE I STOCKHOLDERS 1. CERTIFICATES REPRESENTING STOCK; UNCERTIFICATED SHARES. Subject to any conditions imposed by the General Corporation Law of the State of Delaware (the “General Corporation Law”), the Board of Directors of the corporation may provide by resolution or resolutions that some or all of any |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2023 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 7, 2023 |
EXHIBIT 99.1 Pharma-Bio Serv Retains Investment Banking Firm ACP Capital to Provide Investment Banking and M&A Advisory Services DORADO, PUERTO RICO / ACCESSWIRE / February 7, 2023 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biote |
|
| February 7, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2023 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 30, 2023 |
Pharma-Bio Serv Announces Full Year Results EXHIBIT 99.1 Pharma-Bio Serv Announces Full Year Results DORADO, PUERTO RICO / ACCESSWIRE / January 30, 2023 / Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), is a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industri |
|
| January 30, 2023 |
EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Scienza Labs, Inc. Puerto Rico Pharma-Bio Serv S.L. Spain Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, INC. |
|
| January 30, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2023 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission Fil |
|
| September 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SER |
|
| September 14, 2022 |
EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2022 September 14, 2022 DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2022 / Pharma-Bio Serv, Inc. (?Pharma-Bio Serv? or the ?Company?) (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm providing services to the pharmaceutical, biotechnology, chemical, medical |
|
| September 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 14, 2022 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission F |
|
| June 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2022 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SE |
|
| June 14, 2022 |
Pharma-Bio Serv Announces Results for the Three and Six Months Ended April 30, 2022 Pharma-Bio Serv Announces Results for the Three and Six Months Ended April 30, 2022 June 14, 2022 DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2022 / Pharma-Bio Serv, Inc. |
|
| June 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2022 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 17, 2022 |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2022 EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2022 March 17, 2022 DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2022 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosme |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 17, 2022 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission File |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PH |
|
| February 14, 2022 |
Pharma-Bio Serv Announces Full Year Results and Declares a Special Dividend EXHIBIT 99.1 Pharma-Bio Serv Announces Full Year Results and Declares a Special Dividend February 11, 2022 DORADO, PUERTO RICO / ACCESSWIRE / February 11, 2022 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical dev |
|
| February 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 11, 2022 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 11, 2022 |
EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Scienza Labs, Inc. Puerto Rico Pharma-Bio Serv S.L. Spain Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, INC. |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: October 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR |
|
| November 15, 2021 |
Pharma-Bio Serv Announces Special Dividend EXHIBIT 99.1 Pharma-Bio Serv Announces Special Dividend November 15, 2021 DORADO, PUERTO RICO / ACCESSWIRE / November 15, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied pr |
|
| November 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 15, 2021 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware 0-50956 20-0653570 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 24, 2021 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission |
|
| September 14, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 14, 2021 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission |
|
| September 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SER |
|
| September 14, 2021 |
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2021 EX-99.1 2 pbsvex991.htm PRESS RELEASE EXHIBIT 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2021 DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnolo |
|
| June 25, 2021 |
PBSV / Pharma-Bio Serv, Inc. / PLAZA ELIZABETH - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) PHARMA-BIO SERV, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 71711N 10 0 (CUSIP Number) Elizabeth Plaza Sardinera Beach Building Calle Marginal Costa De Oro C-3, Suite 2 Dorado, Puerto Rico 00646 787-278-2709 (Name, Address and Telep |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 pbsv10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission Fil |
|
| June 14, 2021 |
Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2021 Announces Regulatory and Compliance Advisory Board June 14, 2021 DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, |
|
| June 14, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2021 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission File |
|
| June 3, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2021 Pharma-Bio Serv, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 000-50956 20-0653570 (Commission File |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 30, 2021 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission File |
|
| May 3, 2021 |
DEF 14A 1 pbsvdef14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| March 17, 2021 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO |
|
| March 17, 2021 |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2021 Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2021 March 17, 2021 DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosme |
|
| March 17, 2021 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 17, 2021 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-5 |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No.1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHA |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: October 31, 2020 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Per |
|
| February 1, 2021 |
EX-21.1 2 pbsvex211.htm SUBSIDIARIES OF THE REGISTRANT EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Scienza Labs, Inc. Puerto Rico Pharma-Bio Serv S.L. Spain Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, INC. |
|
| February 1, 2021 |
Pharma-Bio Serv Announces Results for the Year Ended October 31, 2020 Exhibit 99.1 Pharma-Bio Serv Announces Results for the Year Ended October 31, 2020 February 1, 2021 DORADO, PUERTO RICO / ACCESSWIRE / February 1, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), is a compliance, project management and technology transfer support consulting firm. The Company, which provides services to the pharmaceutical, biotechnology, chemical, me |
|
| February 1, 2021 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 1, 2021 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0 |
|
| January 26, 2021 |
SC 13D/A 1 tm212954d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) PHARMA-BIO SERV, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 71711N 10 0 (CUSIP Number) Elizabeth Plaza Sardinera Beach Building Calle Marginal Costa De Oro C-3, Suite 2 Dorado, Puerto Rico 00 |
|
| January 11, 2021 |
8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 7, 2021 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0- |
|
| January 5, 2021 |
Financial Statements and Exhibits, Other Events 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 5, 2021 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0- |
|
| January 5, 2021 |
Exhibit 99.1 Pharma-Bio Serv Announces Appointment of Kirk Michel as Chairman of the Board of Directors and Announces Special Dividend January 5, 2021 DORADO, PUERTO RICO / ACCESSWIRE / January 5, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutic |
|
| September 14, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SER |
|
| June 26, 2020 |
Submission of Matters to a Vote of Security Holders 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 26, 2020 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50 |
|
| June 15, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SE |
|
| June 15, 2020 |
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2020 EX-99.1 2 pbsvex991.htm PRESS RELEASE Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2020 June 15, 2020 DORADO, PUERTO RICO / ACCESSWIRE / June 15, 2020 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology |
|
| June 15, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2020 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission File |
|
| May 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| April 29, 2020 |
PAYCHECK PROTECTION PROGRAM LOAN EX-10.5 6 pbsvex105.htm PAYCHECK PROTECTION PROGRAM LOAN NOTE Exhibit 10.5 PAYCHECK PROTECTION PROGRAM LOAN NOTE SBA Loan # PPP - 22073272-10 SBA Loan Name PHARMA SERV INC Date April 23, 2020 Loan Amount $1,080,400.00 Interest Rate 1.00% Borrower PHARMA SERV INC Operating Company Lender Banco Popular de Puerto Rico . PROMISE TO PAY: In return for the Loan, Borrower promises to pay to the order of |
|
| April 29, 2020 |
PAYCHECK PROTECTION PROGRAM LOAN Exhibit 10.6 PAYCHECK PROTECTION PROGRAM LOAN NOTE SBA Loan # PPP - 29994972-01 SBA Loan Name PHARMA BIO SERV US INC Date April 23, 2020 Loan Amount $94,200.00 Interest Rate 1.00% Borrower PHARMA BIO SERV US INC Operating Company Lender Banco Popular de Puerto Rico . PROMISE TO PAY: In return for the Loan, Borrower promises to pay to the order of Lender the amount of ninety-four thousand two hundr |
|
| April 29, 2020 |
LOAN AGREEMENT FOR PAYCHECK PROTECTION PROGRAM LOAN Exhibit 10.3 LOAN AGREEMENT FOR PAYCHECK PROTECTION PROGRAM LOAN THIS LOAN AGREEMENT ("Agreement") is made between PHARMA BIO SERV US INC ("Borrower"), and Banco Popular de Puerto Rico ("Lender") identified in the attached Authorization by the U.S. Small Business Administration ("SBA") to Lender, dated April 16, 2020 SBA Loan Number 29994972-01 ("Authorization"). WHEREAS, Borrower seeks funds from |
|
| April 29, 2020 |
LOAN AGREEMENT FOR PAYCHECK PROTECTION PROGRAM LOAN EX-10.1 2 pbsvex101.htm LOAN AGREEMENT OF PHARMA-BIO SERV PR, INC. Exhibit 10.1 LOAN AGREEMENT FOR PAYCHECK PROTECTION PROGRAM LOAN THIS LOAN AGREEMENT ("Agreement") is made between PHARMA BIO SERV PR INC ("Borrower"), and Banco Popular de Puerto Rico ("Lender") identified in the attached Authorization by the U.S. Small Business Administration ("SBA") to Lender, dated April 16, 2020 SBA Loan Numbe |
|
| April 29, 2020 |
PAYCHECK PROTECTION PROGRAM LOAN Exhibit 10.4 PAYCHECK PROTECTION PROGRAM LOAN NOTE SBA Loan # PPP - 24986072-10 SBA Loan Name PHARMA BIO SERV PR INC Date April 23, 2020 Loan Amount $757,100.00 Interest Rate 1.00% Borrower PHARMA BIO SERV PR INC Operating Company Lender Banco Popular de Puerto Rico 1 PROMISE TO PAY: In return for the Loan, Borrower promises to pay to the order of Lender the amount of seven hundred fifty-seven tho |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 23, 2020 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 0-50956 20-0653570 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| April 29, 2020 |
LOAN AGREEMENT FOR PAYCHECK PROTECTION PROGRAM LOAN Exhibit 10.2 LOAN AGREEMENT FOR PAYCHECK PROTECTION PROGRAM LOAN THIS LOAN AGREEMENT ("Agreement") is made between PHARMA SERV INC ("Borrower"), and Banco Popular de Puerto Rico ("Lender") identified in the attached Authorization by the U.S. Small Business Administration ("SBA") to Lender, dated April 15, 2020 SBA Loan Number 22073272-10 ("Authorization") WHEREAS, Borrower seeks funds from Lender |
|
| March 16, 2020 |
PBSV / Pharma-Bio Serv, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO |
|
| March 16, 2020 |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2020 Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2020 March 16, 2020 DORADO, PUERTO RICO / ACCESSWIRE / March 16, 2020 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosme |
|
| March 16, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 16, 2020 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission File |
|
| February 28, 2020 |
PBSV / Pharma-Bio Serv, Inc. 10-K/A - Annual Report - AMENDED ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PH |
|
| January 29, 2020 |
Pharma-Bio Serv Announces Results for the Year Ended October 31, 2019 EX-99.1 2 pbsvex991.htm PRESS RELEASE Exhibit 99.1 Pharma-Bio Serv Announces Results for the Year Ended October 31, 2019 January 29, 2020 DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2020 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotech |
|
| January 29, 2020 |
PBSV / Pharma-Bio Serv, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, INC. |
|
| January 29, 2020 |
Description of the Registrant’s securities Exhibit 4.1 DESCRIPTION OF PHARMA-BIO SERV CAPITAL STOCK Pharma-Bio Serv, Inc. ("we," "us," "our," or the "Company") is authorized to issue 50,000,000 shares of common stock, par value $.0001 per share, and 10,000,000 shares of preferred stock, par value $.0001 per share. Common Stock Holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote |
|
| January 29, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2020 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission Fi |
|
| January 29, 2020 |
EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Scienza Labs, Inc. Puerto Rico Pharma-Bio Serv Validation & Compliance Limited Ireland Pharma-Bio Serv S.L. Spain Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil |
|
| December 27, 2019 |
CONSULTING AGREEMENT AMENDMENT Exhibit 10.1 CONSULTING AGREEMENT AMENDMENT CONSULTING AGREEMENT AMENDMENT (this “Amendment”), effective as of January 1, 2020, by and among Pharma-Bio Serv, Inc., a Delaware corporation (the “Company”), Strategic Consultants International, LLC, a Puerto Rico registered Limited Liability Corporation (the “Consultant”), and Elizabeth Plaza, residing in Dorado, Puerto Rico (“Plaza”). W I T N E S S E |
|
| December 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 27, 2019 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission F |
|
| October 28, 2019 |
Financial Statements and Exhibits, Other Events 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 28, 2019 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0 |
|
| October 28, 2019 |
PHARMA-BIO SERV, INC. DECLARES CASH DIVIDEND Exhibit 99.1 PHARMA-BIO SERV, INC. DECLARES CASH DIVIDEND DORADO, PUERTO RICO / ACCESSWIRE / October 28, 2019 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), today announced that its Board of Directors has declared a cash dividend of $0.075 per share. The dividend will be payable on or about November 15, 2019 to shareholders of record at the close of business on November 4, |
|
| October 15, 2019 |
PBSV / Pharma-Bio Serv, Inc. / Hirsh Adam - SCHEDULE 13G Passive Investment Schedule 13G OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 11, 2019 |
Exhibit 10.1 EMPLOYMENT AGREEMENT AMENDMENT EMPLOYMENT AGREEMENT AMENDMENT (this "Amendment"), effective as of October 7, 2019, by and among Pharma-Bio Serv, Inc. with its principal office at 6 Road 696, Dorado, Puerto Rico 00646 (the “Company”), and Pedro J. Lasanta (“Executive”) (both hereinafter “the Parties”). W I T N E S S E T H: WHEREAS, the Company and Executive have entered into that certa |
|
| October 11, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 7, 2019 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission Fil |
|
| September 16, 2019 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 16, 2019 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) |
|
| September 16, 2019 |
Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2019 Exhibit 99.1 Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2019 September 16, 2019 DORADO, PUERTO RICO / ACCESSWIRE / September 16, 2019 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, me |
|
| September 16, 2019 |
PBSV / Pharma-Bio Serv, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SER |
|
| June 14, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2019 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission File |
|
| June 14, 2019 |
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2019 Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2019 DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2019 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and alli |
|
| June 14, 2019 |
PBSV / Pharma-Bio Serv, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SE |
|
| May 29, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 29, 2019 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission File N |
|
| April 26, 2019 |
PBSV / Pharma-Bio Serv, Inc. DEF 14A PROXY STATEMENT DEF 14A 1 pbsvdef14a.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box |
|
| March 18, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 18, 2019 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission File |
|
| March 18, 2019 |
Pharma-Bio Serv Announces Results EX-99.1 2 pbsvex991.htm PRESS RELEASE Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2019 March 18, 2019 DORADO, PUERTO RICO / ACCESSWIRE / March 18, 2019 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechn |
|
| March 18, 2019 |
PBSV / Pharma-Bio Serv, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO |
|
| February 28, 2019 |
PBSV / Pharma-Bio Serv, Inc. AMENDMENT NO. 1 (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PH |
|
| January 29, 2019 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2019 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0 |
|
| January 29, 2019 |
Pharma-Bio Serv Announces Results for the Year Ended October 31, 2018 Exhibit 99.1 Pharma-Bio Serv Announces Results for the Year Ended October 31, 2018 DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2019 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and a |
|
| January 29, 2019 |
EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Scienza Labs, Inc. Puerto Rico Pharma-Bio Serv Validation & Compliance Limited Ireland Pharma-Bio Serv S.L. Spain Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil |
|
| January 29, 2019 |
PBSV / Pharma-Bio Serv, Inc. ANNUAL REPORT (Annual Report) 10-K 1 pbsv10k.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| January 4, 2019 |
CONSULTING AGREEMENT AMENDMENT Exhibit 10.1 CONSULTING AGREEMENT AMENDMENT CONSULTING AGREEMENT AMENDMENT (this “Amendment”), effective as of January 1, 2019, by and among Pharma-Bio Serv, Inc., a Delaware corporation (the “Company”), Strategic Consultants International, LLC, a Puerto Rico registered Limited Liability Corporation (the “Consultant”), and Elizabeth Plaza, residing in Dorado, Puerto Rico (“Plaza”). W I T N E S S E |
|
| January 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 31, 2018 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission F |
|
| October 4, 2018 |
PHARMA-BIO SERV, INC. DECLARES CASH DIVIDEND EX-99.1 2 psvbex991.htm PRESS RELEASE Exhibit 99.1 PHARMA-BIO SERV, INC. DECLARES CASH DIVIDEND DORADO, PUERTO RICO / ACCESSWIRE / October 4, 2018 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), today announced that its Board of Directors has declared a cash dividend of $0.075 per share. The dividend is payable on October 26, 2018 to shareholders of record at the close of b |
|
| October 4, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 4, 2018 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50956 20-0653570 (Commission F |
|
| September 21, 2018 |
Pharma-Bio Serv Announces Closing of Laboratory Assets Sale for $5 Million Exhibit 99.1 Pharma-Bio Serv Announces Closing of Laboratory Assets Sale for $5 Million September 21, 2018 DORADO, PUERTO RICO / ACCESSWIRE / September 21, 2018 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), today announced it has completed the sale of substantially all of the assets of its laboratory business to Romark Global Pharma, LLC for $5 million ($2.0 million in ca |
|
| September 21, 2018 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 17, 2018 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50956 20-0653570 (Commissio |
|
| September 21, 2018 |
PHARMA-BIO SERV, INC. Pro Forma Condensed Consolidated Financial Information Exhibit 99.2 PHARMA-BIO SERV, INC. Pro Forma Condensed Consolidated Financial Information (Unaudited) On September 17, 2018 (the “Closing Date”), Pharma-Bio Serv, Inc. (the “Company”) completed the sale of substantially all of the assets of its laboratory business (the “Laboratory Assets”) pursuant to the Asset Purchase Agreement, dated August 13, 2018, by and between Scienza Labs, Inc. and Romark |
|
| September 14, 2018 |
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2018 Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2018 September 14, 2018 DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2018 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance and project management consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied produc |
|
| September 14, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 14, 2018 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission |
|
| September 14, 2018 |
PBSV / Pharma-Bio Serv, Inc. QUARTERLY REPORT (Quarterly Report) 10-Q 1 pbsv10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| August 17, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 13, 2018 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-50956 20-0653570 (Commission F |
|
| August 17, 2018 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT BY AND AMONG SCIENZA LABS, INC. AND ROMARK GLOBAL PHARMA, LLC August 13, 2018 TABLE OF CONTENTS Page ARTICLE I ASSET PURCHASE; PURCHASE PRICE 1 1.1 Purchase and Sale of Assets 1 1.2 Purchase Price 4 1.3 Closing 4 1.4 Closing Actions and Deliveries 4 1.5 Allocation of Purchase Price 5 ARTICLE II REPRESENTATIONS AND WARRANTIES OF SELLER 6 2.1 Organization and Qua |
|
| June 29, 2018 |
Submission of Matters to a Vote of Security Holders 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 29, 2018 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50 |
|
| June 14, 2018 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2018 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50 |
|
| June 14, 2018 |
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2018 EX-99.1 2 pbsvex991.htm PRESS RELEASE Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2018 June 14, 2018 DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2018 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance and project management consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cos |
|
| June 14, 2018 |
PBSV / Pharma-Bio Serv, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, |
|
| May 25, 2018 |
PBSV / Pharma-Bio Serv, Inc. PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant: ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| March 19, 2018 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 19, 2018 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-5 |
|
| March 19, 2018 |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2018 Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2018 March 19, 2018 DORADO, PUERTO RICO / ACCESSWIRE / March 19, 2018 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic |
|
| March 19, 2018 |
PBSV / Pharma-Bio Serv, Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO |
|
| February 28, 2018 |
PBSV / Pharma-Bio Serv, Inc. AMENDMENT NO. 1 (Annual Report) 10-K/A 1 pbsv10ka.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr |
|
| January 30, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2018 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Co |
|
| January 30, 2018 |
Pharma-Bio Serv Announces Results for the Year Ended October 31, 2017 Blueprint Exhibit 99.1 Pharma-Bio Serv Announces Results for the Year Ended October 31, 2017 DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2018 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food |
|
| January 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, INC. |
|
| January 29, 2018 |
EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Scienza Labs, Inc. Puerto Rico Pharma-Bio Serv Validation & Compliance Limited Ireland Pharma-Bio Serv S.L. Spain Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil |
|
| January 8, 2018 |
8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported):January 8, 2018 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-5 |
|
| January 8, 2018 |
CONSULTING AGREEMENT AMENDMENT Blueprint Exhibit 10.1 CONSULTING AGREEMENT AMENDMENT CONSULTING AGREEMENT AMENDMENT (this ?Amendment?), effective as of January 1, 2018, by and among Pharma-Bio Serv, Inc., a Delaware corporation (the ?Company?), Strategic Consultants International, LLC, a Puerto Rico registered Limited Liability Corporation (the ?Consultant?), and Elizabeth Plaza, residing in Dorado, Puerto Rico (?Plaza?). W I T |
|
| September 28, 2017 |
PHARMA-BIO SERV, INC. PROVIDES OPERATIONAL UPDATE FOLLOWING HURRICANE MARIA Blueprint Exhibit 99.1 PHARMA-BIO SERV, INC. PROVIDES OPERATIONAL UPDATE FOLLOWING HURRICANE MARIA September 28, 2017 DORADO, PUERTO RICO / September 28, 2017 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical devic |
|
| September 28, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 28, 2017 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 ( |
|
| September 14, 2017 |
Blueprint Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2017 September 14, 2017 DORADO, PUERTO RICO / September 14, 2017 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cos |
|
| September 14, 2017 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 14, 2017 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) |
|
| September 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, |
|
| June 14, 2017 |
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2017 EX-99.1 2 pbsvex991.htm PRESS RELEASE Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2017 DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2017 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medi |
|
| June 14, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2017 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commi |
|
| June 14, 2017 |
Pharma-Bio Serv QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, |
|
| May 31, 2017 |
Submission of Matters to a Vote of Security Holders pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 26, 2017 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commis |
|
| April 26, 2017 |
Pharma-Bio Serv DEFINITIVE PROXY STATEMENT Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant: ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as perm |
|
| March 17, 2017 |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2017 EX-99.1 2 pbsvex991.htm PRESS RELEASE Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2017 DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2017 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, m |
|
| March 17, 2017 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 17, 2017 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-5 |
|
| March 17, 2017 |
Pharma-Bio Serv QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SER |
|
| February 28, 2017 |
PBSV / Pharma-Bio Serv, Inc. 10-K/A - Annual Report - 10K/A 10-K/A 1 pbsv10ka.htm 10K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 00 |
|
| January 31, 2017 |
Pharma-Bio Serv ANNUAL REPORT (Annual Report) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO S |
|
| January 31, 2017 |
templatent10k.htm OMB APPROVAL OMB Number: 3235-0058 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Expires: October 31, 2018 Estimated average burden hours per response.......2.50 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: October |
|
| January 31, 2017 |
EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Scienza Labs, Inc. Puerto Rico Pharma-Bio Serv Validation & Compliance Limited Ireland Pharma-Bio Serv S.L. Spain Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil |
|
| January 30, 2017 |
Pharma-Bio Serv Announces Results for the Year Ended October 31, 2016 Blueprint Exhibit 99.1 Pharma-Bio Serv Announces Results for the Year Ended October 31, 2016 DORADO, PUERTO RICO / ACCESSWIRE / January 30, 2017 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food |
|
| January 30, 2017 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 30, 2017 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0 |
|
| January 20, 2017 |
pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 17, 2017 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Co |
|
| January 20, 2017 |
CONSULTING AGREEMENT AMENDMENT EX-10.1 2 pbsvex101.htm CONSULTING AGREEMENT AMENDMENT Exhibit 10.1 CONSULTING AGREEMENT AMENDMENT CONSULTING AGREEMENT AMENDMENT (this "Amendment"), effective as of January 1, 2017, by and among Pharma-Bio Serv, Inc., a Delaware corporation (the “Company”), Strategic Consultants International, LLC, a Puerto Rico registered Limited Liability Corporation (the “Consultant”), and Elizabeth Plaza, res |
|
| September 14, 2016 |
Pharma-Bio Serv QUARTERLY REPORT (Quarterly Report) Blueprint UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA- |
|
| September 14, 2016 |
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2016 EX-99.1 2 pbsvex991.htm PRESS RELEASE Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2016 DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, |
|
| September 14, 2016 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 14, 2016 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) |
|
| June 14, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2016 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commi |
|
| June 14, 2016 |
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2016 Blueprint Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2016 DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food a |
|
| June 14, 2016 |
Pharma-Bio Serv QUARTERLY REPORT (Quarterly Report) pbsv10q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARM |
|
| June 8, 2016 |
pbsvex991.htm Exhibit 99.1 |
|
| June 8, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 8, 2016 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commis |
|
| May 18, 2016 |
Submission of Matters to a Vote of Security Holders pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2016 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commis |
|
| April 13, 2016 |
Pharma-Bio Serv INFORMATION REQUIRED IN PROXY STATEMENT DEF 14A 1 pbsvdef14a.htm INFORMATION REQUIRED IN PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant: o Check the appropr |
|
| March 16, 2016 |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2016 Untitled Document Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2016 DORADO, PUERTO RICO / ACCESSWIRE / March 16, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosme |
|
| March 16, 2016 |
Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 16, 2016 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-5 |
|
| March 16, 2016 |
Pharma-Bio Serv QUARTERLY REPORT (Quarterly Report) 10-Q 1 pbsv10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio |
|
| February 29, 2016 |
Pharma-Bio Serv ANNUAL REPORT AMENDMENT (Annual Report) pbsv10ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA- |
|
| January 29, 2016 |
pbsvex991.htm Exhibit 99.1 Pharma-Bio Serv Announces Total Net Revenues of $23.4 Million and Net Income of $1.6 Million for the Year Ended October 31, 2015 DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2016 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmace |
|
| January 29, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2016 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission Fi |
|
| January 29, 2016 |
EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Pharma-Bio Serv Validation & Compliance Limited Ireland Pharma-Bio Serv S.L. Spain Pharma-Bio Serv Brasil Servicos de Consultoria Ltda. Brazil |
|
| January 29, 2016 |
PBSV / Pharma-Bio Serv, Inc. 10-K - Annual Report - ANNUAL REPORT 10-K 1 pbsv10k.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| January 5, 2016 |
pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 30, 2015 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (C |
|
| January 5, 2016 |
CONSULTING AGREEMENT AMENDMENT pbsvex101.htm Exhibit 10.1 CONSULTING AGREEMENT AMENDMENT CONSULTING AGREEMENT AMENDMENT (this "Amendment"), effective as of January 1, 2016, by and among Pharma-Bio Serv, Inc., a Delaware corporation (the ?Company?), Strategic Consultants International, LLC, a Puerto Rico registered Limited Liability Corporation (the ?Consultant?), and Elizabeth Plaza, residing in Dorado, Puerto Rico (?Plaza?). W |
|
| December 1, 2015 |
pbsvex991.htm Exhibit 99.1 |
|
| December 1, 2015 |
Pharma-Bio Serv to Present at the LD Micro Conference on December 2, 2015 pbsvex992.htm Exhibit 99.2 Pharma-Bio Serv to Present at the LD Micro Conference on December 2, 2015 DORADO, PUERTO RICO / ACCESSWIRE / November 24, 2015 / Pharma-Bio Serv, Inc. (PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries |
|
| December 1, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 24, 2015 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) |
|
| September 14, 2015 |
CONSULTING AGREEMENT AMENDMENT EX-10.1 2 pbmsex101.htm CONSULTING AGREEMENT AMENDMENT Exhibit 10.1 CONSULTING AGREEMENT AMENDMENT CONSULTING AGREEMENT AMENDMENT (this "Amendment"), effective as of July 1, 2015, by and among Pharma-Bio Serv, Inc., a Delaware corporation (the “Company”), Strategic Consultants International, LLC, a Puerto Rico registered Limited Liability Corporation (the “Consultant”), and Elizabeth Plaza, residi |
|
| September 14, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 14, 2015 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) |
|
| September 14, 2015 |
Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2015 pbsvex991.htm Exhibit 99.1 Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2015 DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical de |
|
| September 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, I |
|
| September 1, 2015 |
pbsvex991.htm Exhibit 99.1 |
|
| September 1, 2015 |
Pharma-Bio Serv CURRENT REPORT (Current Report/Significant Event) pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 31, 2015 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Com |
|
| September 1, 2015 |
Pharma-Bio Serv to Present at the Sidoti Emerging Growth Conference pbsvex992.htm Exhibit 99.2 Pharma-Bio Serv to Present at the Sidoti Emerging Growth Conference DORADO, PUERTO RICO / ACCESSWIRE / August 31, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, foo |
|
| June 15, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2015 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commi |
|
| June 15, 2015 |
Pharma-Bio Serv Announces Results for the Three and Six Months Ended April 30, 2015 pbsvex991.htm Exhibit 99.1 Pharma-Bio Serv Announces Results for the Three and Six Months Ended April 30, 2015 DORADO, PUERTO RICO / ACCESSWIRE / June 15, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, |
|
| June 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, |
|
| May 5, 2015 |
Submission of Matters to a Vote of Security Holders 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 1, 2015 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-5095 |
|
| March 31, 2015 |
Pharma-Bio Serv DEFINITIVE PROXY STATEMENT DEF 14A 1 pbsvdef14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant: o Check the appropriate box: o P |
|
| March 17, 2015 |
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2015 pbsvex991.htm Exhibit 99.1 Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2015 DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, |
|
| March 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 pbsv10q.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio |
|
| March 17, 2015 |
Pharma-Bio Serv CURRENT REPORT (Current Report/Significant Event) pbsv8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 17, 2015 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Comm |
|
| March 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, INC |
|
| January 30, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 29, 2015 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission Fi |
|
| January 30, 2015 |
Exhibit 99.1 Pharma-Bio Serv Announces Total Net Revenues of $27.6 Million and Net Income of $2.4 Million for the Year Ended October 31, 2014 DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2015 / Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotec |
|
| January 29, 2015 |
EXHIBIT 21.1 Subsidiary Name Jurisdiction of Organization Pharma-Bio Serv PR, Inc. Puerto Rico Pharma-Bio Serv US, Inc. Delaware Pharma Serv, Inc. Puerto Rico Pharma-Bio Serv Validation & Compliance Limited Ireland Pharma-Bio Serv S.L. Spain |
|
| January 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2014 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-50956 PHARMA-BIO SERV, INC. |
|
| January 5, 2015 |
Employment Agreement, effective January 1, 2015, between Pharma-Bio Serv, Inc. and Victor Sanchez EX-10.2 3 pbsvex102.htm EMPLOYMENT AGREEMENT Exhibit 10.2 EMPLOYMENT AGREEMENT AGREEMENT dated and effective as of January 1, 2015 (the “Effective Date”) by and among Pharma-Bio Serv, Inc. with its principal office at 6 Road 696, Dorado, Puerto Rico 00646 (the “Company”) and Victor Sanchez Altura (“Executive”) (hereinafter “the Parties”). WITNESSETH: WHEREAS, the Company desires to appoint Executi |
|
| January 5, 2015 |
8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 1, 2015 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0- |
|
| January 5, 2015 |
CONSULTING AGREEMENT AMENDMENT Exhibit 10.1 CONSULTING AGREEMENT AMENDMENT CONSULTING AGREEMENT AMENDMENT (this "Amendment"), effective as of January 1, 2015, by and among Pharma-Bio Serv, Inc., a Delaware corporation (the “Company”), Strategic Consultants International, LLC, a Puerto Rico registered Limited Liability Corporation (the “Consultant”), and Elizabeth Plaza, residing in Dorado, Puerto Rico (“Plaza”). W I T N E S S E |
|
| December 19, 2014 |
8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 15, 2014 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) |
|
| December 2, 2014 |
Exhibit 99.1 Pharma-Bio Serv Appoints Víctor Sánchez as President and Chief Executive Officer Effective January 1, 2015 DORADO, PUERTO RICO, December 2, 2014 – Pharma-Bio Serv, Inc. (Pharma-Bio Serv or the Company) (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, that provides services to the pharmaceutical, biotechnology, chemical, medical device, c |
|
| December 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 1, 2014 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-50956 20-0653570 (Commission Fi |
|
| December 1, 2014 |
Pharma-Bio Serv to Present at the LD Micro Conference on December 2, 2014 Exhibit 99.2 Pharma-Bio Serv to Present at the LD Micro Conference on December 2, 2014 DORADO, PUERTO RICO, November 25, 2014, Pharma-Bio Serv, Inc. (OTCQB: PBSV), a compliance, project management and technology transfer support consulting firm, announced today that the Company will be a featured presenter at the LD MICRO Main Event VII Conference at the Luxe Sunset, Los Angeles, CA on Tuesday, De |
|
| December 1, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 pbsv8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 25, 2014 Pharma-Bio Serv, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) |
|
| December 1, 2014 |
EX-99.1 2 pbsvex991.htm PRESENTATION SLIDES Exhibit 99.1 |
